During the last 25 years, the treatment of Diffuse Large B-cell Lymphoma (DLBCL) has not been changed: chemotherapy plus rituximab. For fit patients, autologous stem cell transplantation as second-line consolidation and allogeneic hematopoietic cell transplantation in case of further relapses. With these approaches, less than 55%-60% of patients are finally cured and inferior outcomes are generally reported for patients with high-risk characteristics. Thus, newer therapeutical approaches are needed.
Hopefully, with the advent of newer immunotherapies, the therapeutic scenario for DLBCL is finally improving. The introduction of anti-CD19 chimeric-antigen receptor T cells for relapsed/refractory disease rapidly changed the survival of patients. Decreased toxicity compared to transplant strategies, expanded the therapeutic scenario also to elderly and frailer patients. Nowadays, cell therapies are improving its efficacy and newer immunotherapies, such as bispecific monoclonal antibodies, newer monoclonal antibodies and immunoconjugates, are showing promising results. A better biological knowledge of diffuse large B cell lymphoma pathogenesis has allowed to identify other therapeutic targets dealing with the genetic, epigenetic, metabolic profile of this heterogeneous type of lymphoma.
In this Research Topic we welcome the submissions of Review, Mini Review, Perspective, Clinical Trial and Original Research articles on the following, and related, subtopics:
• newer immunotherapies for DLBCL (e.g., allogeneic hematopoietic cell transplantation, cell therapies, bispecific antibodies, immunoconjugates)
• newer therapeutic strategies other than immunotherapies for DLBCL
• newer diagnostic strategies for DLBCL
• studies that describe the cellular response to immunotherapies during the treatment and prediction of patients who could benefit from these therapies (predictive biomarkers).
Topic Editor Alberto Mussetti received financial support from Gilead. Topic Editor Enrico Derenzini received financial support from TG-Therapeutics, ADC-Therapeutics, and Takeda and he is on the Advisory board for Gilead, Astra Zeneca, Takeda, and Beigene. The other Topic Editors declare no competing interests.
During the last 25 years, the treatment of Diffuse Large B-cell Lymphoma (DLBCL) has not been changed: chemotherapy plus rituximab. For fit patients, autologous stem cell transplantation as second-line consolidation and allogeneic hematopoietic cell transplantation in case of further relapses. With these approaches, less than 55%-60% of patients are finally cured and inferior outcomes are generally reported for patients with high-risk characteristics. Thus, newer therapeutical approaches are needed.
Hopefully, with the advent of newer immunotherapies, the therapeutic scenario for DLBCL is finally improving. The introduction of anti-CD19 chimeric-antigen receptor T cells for relapsed/refractory disease rapidly changed the survival of patients. Decreased toxicity compared to transplant strategies, expanded the therapeutic scenario also to elderly and frailer patients. Nowadays, cell therapies are improving its efficacy and newer immunotherapies, such as bispecific monoclonal antibodies, newer monoclonal antibodies and immunoconjugates, are showing promising results. A better biological knowledge of diffuse large B cell lymphoma pathogenesis has allowed to identify other therapeutic targets dealing with the genetic, epigenetic, metabolic profile of this heterogeneous type of lymphoma.
In this Research Topic we welcome the submissions of Review, Mini Review, Perspective, Clinical Trial and Original Research articles on the following, and related, subtopics:
• newer immunotherapies for DLBCL (e.g., allogeneic hematopoietic cell transplantation, cell therapies, bispecific antibodies, immunoconjugates)
• newer therapeutic strategies other than immunotherapies for DLBCL
• newer diagnostic strategies for DLBCL
• studies that describe the cellular response to immunotherapies during the treatment and prediction of patients who could benefit from these therapies (predictive biomarkers).
Topic Editor Alberto Mussetti received financial support from Gilead. Topic Editor Enrico Derenzini received financial support from TG-Therapeutics, ADC-Therapeutics, and Takeda and he is on the Advisory board for Gilead, Astra Zeneca, Takeda, and Beigene. The other Topic Editors declare no competing interests.
